Design Therapeutics Inc. is a clinical-stage biopharmaceutical company headquartered in Carlsbad, California, focused on pioneering therapies for degenerative disorders associated with nucleotide repeat expansions, such as Friedreich's ataxia. The company is advancing a proprietary pipeline of small-molecule drug candidates aimed at addressing the underlying genetic mechanisms of these diseases to restore normal cellular function and improve patient outcomes. With a commitment to tackling significant unmet medical needs, Design Therapeutics is strategically positioned to impact the biopharmaceutical landscape, especially in the niche of rare genetic diseases. Show more
Location: 6005 HIDDEN VALLEY ROAD, CARLSBAD, CA, UNITED STATES, 92011, Carlsbad, CA, 92011, USA | Website: https://www.designtx.com | Industry: BIOTECHNOLOGY | Sector: HEALTHCARE
Market Cap
581.6M
52 Wk Range
$2.60 - $10.97
Previous Close
$10.57
Open
$10.48
Volume
453,530
Day Range
$9.82 - $10.69
Enterprise Value
397.9M
Cash
15.09M
Avg Qtr Burn
-11.16M
Insider Ownership
35.97%
Institutional Own.
59.27%
Qtr Updated
09/30/25
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
| Drug & Indication | Stage & Event | Catalyst Date |
|---|---|---|
DT-168 Details Fuchs Endothelial Corneal Dystrophy , Eye disease | Phase 2 Data readout | |
DT-216P2 Details Friedreich’s Ataxia | Phase 1/2 Data readout | |
DT-818 (GeneTAC Modulator) Details Myotonic Dystrophy Type-1 (DM1) | Phase 1 Initiation |
